New Guidelines Issued for CLN2 Diagnosis, Management

New Guidelines Issued for CLN2 Diagnosis, Management

295223

New Guidelines Issued for CLN2 Diagnosis, Management

An international team of experts has provided the latest evidence-based recommendations for diagnosis, assessment, management, and treatment of neuronal ceroid lipofuscinosis type 2 (CLN2), a study reported.  The study, “Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients,” was published in the Orphanet Journal of Rare Diseases. CLN2, also known as late infantile Batten disease, is a rare, inherited neurodegenerative disorder caused by a deficiency in the TPP1 enzyme due to mutations…

You must be logged in to read/download the full post.